D. Ackermann

D. Ackermann is a highly accomplished individual with a vast educational background and extensive experience in the field of biomedical engineering, neuroengineering, and ophthalmology.

Having pursued advanced degrees including a Ph.D. in Biomedical Engineering specializing in Neuroengineering from Case Western Reserve University, a Master of Science in Biomedical Engineering from the same institution, and a Bachelor of Engineering in Biomedical Engineering from Vanderbilt University, D. Ackermann has a strong academic foundation.

Notably, Ackermann has been involved in various prestigious roles in organizations such as serving as the Director of Biotechnology at the Stanford Byers Center for Biodesign and as the CEO of Presidio Medical, Inc. Additionally, Ackermann has held positions including Chairman at Oyster Point Pharma, Inc., Vice President of Neurostimulation at Allergan, and President & CEO of Oculeve, Inc.

In addition to his professional roles, Ackermann has also been associated with renowned institutions like Stanford University and Case Western Reserve University, where he has served as a Research Fellow, Vision Research Fellow, Postdoctoral Scholar, and as a Co-Instructor for the Biodesign Innovation Course.

His contributions extend to advisory and board memberships in notable companies including Vensana Capital, Presidio Medical, Inc., and Tarsus Pharmaceuticals, Inc. Ackermann's broad range of experiences showcases his expertise and leadership in the healthcare and biotechnology sectors.

With an impressive portfolio and a history of impactful positions and educational achievements, D. Ackermann stands as a seasoned professional in the fields of biomedical engineering, ophthalmology, and neuroengineering.